Relay Therapeutics vs Surrozen
Relay Therapeutics is the larger business, with $15.4m of revenue in fiscal 2025 against $3.5m for Surrozen (4.4 times as much). Relay Therapeutics grew faster (53.4% against -67.4%). Relay Therapeutics kept more of each dollar of sales as profit: a net margin of -1800.6% against -6960.8%.
| Latest fiscal year | Relay TherapeuticsRLAY, 2025 | SurrozenSRZN, 2025 |
|---|---|---|
| Revenue | $15.4m | $3.5m |
| Revenue growth | 53.4% | -67.4% |
| Net income | −$276m | −$242m |
| Operating margin | -1971.6% | -1210.6% |
| Net margin | -1800.6% | -6960.8% |
| Return on equity | -41.1% | — |
| Free cash flow | −$236m | −$30.4m |
| Cash | $84.0m | $89.2m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 192 | 44 |
| Market value | $3.84bn | $351m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | — |
| Insider trades, 12 months | 0 buys, 40 sales | 53 buys, 6 sales |